Fior Markets launched a study titled “Alzheimer’s Therapeutics Market by Drug Type (Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonist, Others), Distribution Channel, Regions”,and Global Forecast 2019-2026.
The global Alzheimer’s therapeutics market is expected to grow from USD 4.36 Billion in 2018 to USD 8.19 Billion by 2026, at a CAGR of 8.20% during the forecast period 2019-2026. Growing research and development activities for finding new curative therapies and increasing government and institutional support for research activities, and rising geriatric population are the factors to drive the market growth.
DOWNLOAD FREE SAMPLE REPORT AT:https://www.fiormarkets.com/report-detail/396100/request-sample
The NMDA segment had a market value of USD 2.37 billion in 2018
The drug type segment is divided into cholinesterase inhibitors, N-methyl-D-aspartate (NMDA) receptor antagonist and others. The others drug type segment containing monoclonal antibodies and Tau targeting proteins are anticipated to grow at the highest CAGR of 10.29% over the forecast period. On the other hand,N-methyl-D-aspartate (NMDA) receptor antagonist segment dominated the global Alzheimer’s therapeutics market with USD 2.37 billion revenue in 2018. The use of the monoclonal antibodies for improving drugs for treating Alzheimer’s has increased. In addition, monoclonal antibodies are widely used in the diagnostic tests, analytic and chemical uses, therapeutic, and cancer treatment applications.
The hospital pharmacysegment had a market value of USD 2.79 billion in 2018
The distribution channel segment includes hospital pharmacy, retail pharmacy and online sales. On account of the increased patient hospitalization for the treatment of Alzheimer’s, the hospital pharmacy led the global Alzheimer’s therapeutics market with USD 2.79 billion revenue in 2018. The growing geriatric population dealing with weak immune system has widely increased the occurrence of the target diseases. The availability of large range of the medications for the detection of Alzheimer’s has increased the hospital pharmacy segment market share in the global Alzheimer’s therapeutics market.
Regional Segmentation Analysis:
The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. Favorable reimbursement policies, well-developed healthcare facilities as well as high incidence of Alzheimer’s disease were some of the factors that led the North America region to dominate the global Alzheimer’s therapeutics market with USD 1.87 billion revenue in 2018. Europe region accounted for a significant share of global Alzheimer’s therapeutics market due to easy availability of the cutting edge therapeutics and diagnostics.
Alzheimers illness is a neurode generative issue that for the most part happens with seniority and is one of the main source of dementia. Dementia strives in type of memory misfortune and other intellectual capacities genuine enough to meddle with everyday life. Alzheimer’s declines over the time.Increasing prevalence of Alzheimer’s disease as well as growing institutional support for research activities are driving the global Alzheimer’s therapeutics market. In addition, introduction of new and innovative technologies and drugs will help to boost the market growth. The high cost of treatment and stringent drug approval process are expected to restrain the market growth over the forecast period. Nevertheless, use of artificial intelligence and cloud-based cognitive assessment systems will expand the market size in upcoming years.
Browse full report with TOC at:https://www.fiormarkets.com/report/alzheimer-s-therapeutics-market-by-drug-type-cholinesterase-inhibitors-396100.html
Major players in the global Alzheimer’s therapeutics market are Pfizer, Inc., Merck & Co. Inc., Novartis AG, Eisai Co. Ltd., H. Lundbeck A/S, AC Immune, TauRx Pharmaceuticals Ltd., Actavis plc., Forest Laboratories,TevaPharmaceuticals Industries Ltd., Janssen Pharmaceutical, GE healthcare, Eli Lilly and Company, DiaGenic ASA, VTV Therapeutics, Hoffman-La Roche Ltd., AstraZeneca, and Daiichi Sankyo Company Ltd., among others. In order to enhance the market position, the key players are now focusing on adopting strategies such as product innovations, mergers & acquisitions, recent developments, joint venture, collaborations, and partnership. For instance in 2016, AC Immune announced its collaboration with Biogen for the development of protein ligands so as to target the proteins that are involved in the pathogenesis of neurological disorders.
Customization of the Report:This report can be customized to meet the client’s requirements. Please connect with our sales team (firstname.lastname@example.org), who will ensure that you get a report that suits your needs.